Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 7/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | AQP1 | P29972 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17987807 | 0.88 | EZH2 (0.45) | EZH2RORCACACBACACADRD2 | |
| SCHEMBL17987846 | 0.86 | RORC (0.41) | RORCAAK1DRD2NAMPT | |
| SCHEMBL15765023 | 0.85 | MEN1 (0.38) | RORCAAK1DRD2NAMPT | |
| SCHEMBL15765046 | 0.84 | EZH2 (0.47) | EZH2RORCACACBACACADRD2 | |
| SCHEMBL15758852 | 0.83 | EZH2 (0.46) | EZH2SIRT2AKR1B1AQP1 | |
| SCHEMBL15765204 | 0.83 | ACACB (0.43) | EZH2RORCACACBACACADRD2 | |
| SCHEMBL15765045 | 0.82 | EZH2 (0.40) | EZH2RORCACACBACACADRD2 | |
| SCHEMBL15765200 | 0.82 | EZH2 (0.40) | EZH2RORCACACBACACADRD2 | |
| SCHEMBL5793270 | 0.81 | DRD2 (0.46) | EZH2RORCACACBACACADRD2 | |
| SCHEMBL15765198 | 0.81 | EZH2 (0.39) | EZH2RORCACACBACACADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938258-B2 | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-04-10 | — | — | US | disclosed |
| WO-2017117447-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | Karyopharm Therapeutics Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | Karyopharm Therapeutics Inc. | 2016-08-04 | — | — | US | disclosed |
| WO-2014085607-A1 | SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2014-06-05 | — | — | WO | disclosed |
| WO-2006000902-A1 | DIHYDROBENZOFURAN COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | BCL6, MALT1, BCL3 | EZH2 469/4885RORC 281/4885SIRT2 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.